[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Samsung Med Ctr, Dept Hematol Oncol, Seoul, South Korea
[3] Med Univ Gdansk, Dept Oncol Radiotherapy, Gdansk, Poland
[4] Med Univ Gdansk, Early Phase Clin Trials, Gdansk, Poland
[5] Int Ctr Thorac Cancers CICT, Dept Med Oncol, Villejuif, France
[6] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[7] Asan Med Ctr, Dept Oncol, Seoul, South Korea
[8] Seoul Natl Univ, Div Hematol & Med Oncol, Dept Internal Med, Bundang Hosp, Seongnam, South Korea
[9] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
[10] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[11] Chinese Acad Sci, Inst Basic Med & Canc, Hangzhou, Zhejiang, Peoples R China
[12] Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp Crit Care Med, Klin Floridsdorf, Vienna, Austria
[13] European Inst Oncol IRCSS, Thorac Oncol Div, Milan, Italy
[14] San Camillo Forlanini Hosp, Pneumo Oncol Unit, Rome, Italy
[15] Dnipropetrovsk Med Acad, Oncol & Med Radiol Dept, Dnipro, Ukraine
[16] F Hoffmann Roche Ltd, PD Oncol, Basel, Switzerland
[17] Roche China Holding Ltd, Dept Clin Sci, Shanghai, Peoples R China
[18] F Hoffmann Roche Ltd, Data & Stat Sci, Basel, Switzerland
[19] F Hoffmann Roche Ltd, Product Dev Med Affairs, Basel, Switzerland
[20] F Hoffmann Roche Ltd, PD Safety Risk Management, Basel, Switzerland
[21] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China